Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Clinical setbacks for toll-like receptor 9 agonists in cancer

Nature Biotechnology volume 25, pages 825–826 (2007)Cite this article

Cancer failures are not deterring interest in toll-like receptor agonists for other high profile indications.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Portland, Maine

    Charlie Schmidt

Authors
  1. Charlie Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Toll-like receptor therapies compete to reduce side effects

Web links

Coley Pharmaceutical

Idera Pharmaceuticals

Dynavax

VaxInnate

Eisai

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 25, 825–826 (2007). https://doi.org/10.1038/nbt0807-825

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0807-825

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing